机构:[1]Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院[2]Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.四川大学华西医院
Lipid transfer proteins (LTPs) are crucial players in nonvesicular lipid trafficking. LTPs sharing a lipocalin lipid transfer domain (lipocalin-like proteins) have a wide range of biological functions, such as regulating immune responses and cell proliferation, differentiation, and death as well as participating in the pathogenesis of inflammatory, metabolic, and neurological disorders and cancer. Therefore, the development of small-molecule inhibitors targeting these LTPs is important and has potential clinical applications. Herein, we summarize the structure and function of lipocalin-like proteins, mainly including retinol-binding proteins, lipocalins, and fatty acid-binding proteins and discuss the recent advances on small-molecule inhibitors for these protein families and their applications in disease treatment. The findings of our Perspective can provide guidance for the development of inhibitors of these LTPs and highlight the challenges that might be faced during the procedures.
基金:
This work was supported by the National Natural Science
Foundation of China (82273559, 22177084 and 82073473),
the Fundamental Research Funds of Science & Technology
Department of Sichuan Province (2022YFQ0054), the China
Postdoctoral Science Foundation (2023T160446), and the
1.3.5 project for disciplines of excellence, West China Hospital,
Sichuan University (ZYJC21036 and 2023HXBH032).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|1 区医学
小类|1 区药物化学
最新[2023]版:
大类|1 区医学
小类|1 区药物化学
第一作者:
第一作者机构:[1]Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu 610041, China.[2]Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
通讯作者:
通讯机构:[1]Department of Dermatology & Venerology, West China Hospital, Sichuan University, Chengdu 610041, China.[2]Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
推荐引用方式(GB/T 7714):
Chen Siliang,Pan Zhaoping,Liu Mingxia,et al.Recent Advances on Small-Molecule Inhibitors of Lipocalin-like Proteins[J].Journal Of Medicinal Chemistry.2024,doi:10.1021/acs.jmedchem.4c00086.
APA:
Chen Siliang,Pan Zhaoping,Liu Mingxia,Guo Linghong,Jiang Xian&He Gu.(2024).Recent Advances on Small-Molecule Inhibitors of Lipocalin-like Proteins.Journal Of Medicinal Chemistry,,
MLA:
Chen Siliang,et al."Recent Advances on Small-Molecule Inhibitors of Lipocalin-like Proteins".Journal Of Medicinal Chemistry .(2024)